Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
EAGLE PHARMACEUTICALS, INC. (EGRX)
|
Add to portfolio |
|
|
|
| Price: |
$52.40
| | Metrics |
| OS: |
13.0
|
M
| |
5
|
% ROE
|
| Market cap: |
$681
|
M
| |
|
|
|
Net debt:
|
$54.8
|
M
| |
0.9
|
x Debt/EBITDA
|
|
EV:
|
$735
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$61.6
|
M
| |
11.9
|
x EV/EBITDA
|
|
EBIT
|
$41.0
|
M
| |
17.9
|
x EV/EBIT
|
| EPS |
$0.91
| |
57.4
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 316.6 | 171.5 | 187.8 | 195.9 | 213.3 | 236.7 | 189.5 | 66.2 |
| Revenue growth | 84.6% | -8.7% | -4.1% | -8.2% | -9.9% | 24.9% | 186.1% | |
| Cost of goods sold | 85.5 | 31.5 | 33.6 | 47.9 | 42.4 | 33.7 | 35.8 | 7.8 |
| Gross profit | 231.2 | 140.0 | 154.2 | 148.0 | 170.9 | 203.0 | 153.7 | 58.5 |
| Gross margin | 73.0% | 81.6% | 82.1% | 75.6% | 80.1% | 85.8% | 81.1% | 88.3% |
| Selling, general and administrative | 106.6 | 75.3 | 78.6 | 76.4 | 60.5 | 71.4 | 53.3 | 20.2 |
| Research and development | 34.1 | 51.3 | 30.8 | 36.8 | 44.4 | 32.6 | 28.3 | 27.9 |
| EBITA | 92.3 | 5.8 | 35.6 | 24.3 | 49.0 | 78.3 | 53.5 | 2.6 |
| EBITA margin | 29.2% | 3.4% | 19.0% | 12.4% | 23.0% | 33.1% | 28.2% | 3.9% |
| Amortization of intangibles | 11.4 | 3.0 | 2.7 | 2.5 | 2.5 | 2.8 | 0.9 | |
| EBIT | 81.0 | 2.8 | 33.0 | 21.8 | 46.5 | 75.5 | 52.6 | 2.6 |
| EBIT margin | 25.6% | 1.6% | 17.5% | 11.1% | 21.8% | 31.9% | 27.7% | 3.9% |
| Pre-tax income | 61.4 | -4.5 | 22.7 | 22.0 | 34.0 | 72.9 | 53.4 | 2.6 |
| Income taxes | 25.8 | 4.1 | 10.7 | 7.7 | 2.1 | 21.0 | -28.0 | 0.0 |
| Tax rate | 42.0% | | 47.1% | 34.9% | 6.3% | 28.8% | | 0.1% |
| Net income | 35.6 | -8.6 | 12.0 | 14.3 | 31.9 | 51.9 | 81.5 | 2.6 |
| Net margin | 11.3% | -5.0% | 6.4% | 7.3% | 15.0% | 21.9% | 43.0% | 3.9% |
| |
| Diluted EPS | $2.73 | ($0.66) | $0.87 | $1.01 | $2.09 | $3.27 | $4.96 | $0.16 |
| Shares outstanding (diluted) | 13.1 | 13.1 | 13.8 | 14.1 | 15.3 | 15.9 | 16.4 | 16.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|